Follow-up recommendations from CHMP on novel influenza (H1N1) outbreak: Tamiflu (oseltamivir); Relenza (zanamivir)

Author (Corporate)
Publisher
Publication Date 29/05/2009
Content Type

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA), on 29 May 2009, adopted a number of follow-up recommendations relating to the use of medicines for the treatment of human swine influenza.

Subject Categories
Countries / Regions